|
We continue to cultivate our established cardiovascular and central nervous system therapeutic franchises while exploring
new product opportunities that will better serve important treatment needs in
the patient population.
Read about our therapeutic areas:
Cardiovascular
If left untreated, high blood pressure can lead to heart disease and stroke.
Because blood pressure is controlled by a number of biological factors,
patients and physicians depend on a variety of treatment options. Forest's high
blood pressure treatment therapies—Bystolic® (nebivolol) and Tiazac®
(diltiazem hydrochloride)—work in different ways to manage a condition that affects nearly 1 in 3 Americans.
Central Nervous System
The central nervous system communicates through a complex and intricate network of transmissions, making treatment a challenge for conditions such as depression, anxiety, Alzheimer's disease and alcohol dependence. Forest has developed a portfolio of therapies designed to manage these conditions: Lexapro® (escitalopram oxalate) for major depressive disorder and generalized anxiety disorder, which together affect approximately 20 – 30 million people in the United States; Celexa® (citalopram hydrobromide) for depression; Namenda® (memantine HCl) for moderate and severe Alzheimer's disease, which currently affects an estimated 5 million Americans; and Campral® (acamprosate calcium) for alcohol dependence in association with psychosocial support.
Endocrinology
The endocrine system helps regulate metabolic activity in the body. The thyroid
gland plays a key role within the endocrine system by producing hormones that
help cells convert oxygen and calories into energy. Thyroid medications are
among the most prescribed in the U.S., with approximately 27 million Americans
suffering from thyroid diseases. Forest offers three products to help treat
these diseases: Armour®Thyroid (thyroid
tablets, USP), Levothroid® (levothyroxine
sodium tablets, USP), and Thyrolar® (liotrix
tablets, USP).
Ob/Gyn
In the Ob/Gyn area, Forest has developed treatments for patients
undergoing complications during labor.
Of the approximately 4 million births every year in the U.S., 21% will
require induction of labor. Cervidil® Vaginal
Insert (dinoprostone, 10 mg), is the only FDA-approved removable
product for ripening the cervix, the process by which the cervix becomes more
compliant and which must take place before induction can be safely undertaken.
Pain Management
Acute pain is the most common reason patients seek medical attention. Each
year, about 25 million Americans experience acute pain as a result of injury or
surgery. Forest offers a combination pain product,
Combunox® (oxycodone HCl 5mg and ibuprofen 400 mg) Tablets CII, to help
manage acute, moderate to severe pain for up to seven days.
Combunox is a combination opioid / non-opioid pain medication approved for the
management of acute, moderate to severe pain. Combunox is the first and only
medication to combine 5 mg of oxycodone HCl and 400 mg of ibuprofen, the
highest dose of ibuprofen available in a combination opioid product.
Respiratory
Inflamed airways caused by asthma can interfere with the ability to breathe.
Forest provides metered-dose inhaler medication,
Aerobid® (flunisolide), to help manage the inflammation caused by
asthma. AeroChamber Plus® is a
holding chamber device designed to maximize the delivery of metered-dose
inhaler medications to patients' lungs.
Respiratory distress syndrome (RDS) is a lung condition that can occur in
premature infants whose lungs have not completely developed.
Infasurf® (calfactant) is indicated to treat and prevent this condition
and has been used by over 100,000 infants.
Healthcare Professionals
If you are a healthcare professional and have a question(s) or need information
about a specific Forest product, please contact Forest's Medical Information and Communication Department at 800-678-1605, extension 66297.
Consumers
For consumer or patient-related questions, please contact your healthcare
provider.
|
